Radiotherapeutic strategies in the management of hepatocellular carcinoma

Ik Jae Lee, Jinsil Seong

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Although potentially curative therapies for hepatocellular carcinoma (HCC) are well established, they are offered only to a limited number of patients. For advanced HCC, sorafenib is now the treatment of choice. Radiotherapy technology has evolved remarkably during the past decade and can be precisely delivered, thereby permitting higher doses to the tumor and reduced doses to surrounding normal tissues. According to the Korean Liver Cancer Study Group (KLCSG) practice guidelines, radiation therapy is considered appropriate for unresectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B, and tumors occupying less than two thirds of the liver with level II evidence. In this review, we discuss the radiotherapeutic strategies for each clinical setting in patients with HCC.

Original languageEnglish
Pages (from-to)123-133
Number of pages11
JournalOncology
Volume81
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

Hepatocellular Carcinoma
Radiotherapy
Group Practice
Liver Neoplasms
Practice Guidelines
Neoplasms
Neoplasm Metastasis
Technology
Liver
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lee, Ik Jae ; Seong, Jinsil. / Radiotherapeutic strategies in the management of hepatocellular carcinoma. In: Oncology. 2011 ; Vol. 81, No. SUPPL. 1. pp. 123-133.
@article{209198255a56457c99d2883abb16eab6,
title = "Radiotherapeutic strategies in the management of hepatocellular carcinoma",
abstract = "Although potentially curative therapies for hepatocellular carcinoma (HCC) are well established, they are offered only to a limited number of patients. For advanced HCC, sorafenib is now the treatment of choice. Radiotherapy technology has evolved remarkably during the past decade and can be precisely delivered, thereby permitting higher doses to the tumor and reduced doses to surrounding normal tissues. According to the Korean Liver Cancer Study Group (KLCSG) practice guidelines, radiation therapy is considered appropriate for unresectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B, and tumors occupying less than two thirds of the liver with level II evidence. In this review, we discuss the radiotherapeutic strategies for each clinical setting in patients with HCC.",
author = "Lee, {Ik Jae} and Jinsil Seong",
year = "2011",
month = "12",
day = "1",
doi = "10.1159/000333275",
language = "English",
volume = "81",
pages = "123--133",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "SUPPL. 1",

}

Radiotherapeutic strategies in the management of hepatocellular carcinoma. / Lee, Ik Jae; Seong, Jinsil.

In: Oncology, Vol. 81, No. SUPPL. 1, 01.12.2011, p. 123-133.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Radiotherapeutic strategies in the management of hepatocellular carcinoma

AU - Lee, Ik Jae

AU - Seong, Jinsil

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Although potentially curative therapies for hepatocellular carcinoma (HCC) are well established, they are offered only to a limited number of patients. For advanced HCC, sorafenib is now the treatment of choice. Radiotherapy technology has evolved remarkably during the past decade and can be precisely delivered, thereby permitting higher doses to the tumor and reduced doses to surrounding normal tissues. According to the Korean Liver Cancer Study Group (KLCSG) practice guidelines, radiation therapy is considered appropriate for unresectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B, and tumors occupying less than two thirds of the liver with level II evidence. In this review, we discuss the radiotherapeutic strategies for each clinical setting in patients with HCC.

AB - Although potentially curative therapies for hepatocellular carcinoma (HCC) are well established, they are offered only to a limited number of patients. For advanced HCC, sorafenib is now the treatment of choice. Radiotherapy technology has evolved remarkably during the past decade and can be precisely delivered, thereby permitting higher doses to the tumor and reduced doses to surrounding normal tissues. According to the Korean Liver Cancer Study Group (KLCSG) practice guidelines, radiation therapy is considered appropriate for unresectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B, and tumors occupying less than two thirds of the liver with level II evidence. In this review, we discuss the radiotherapeutic strategies for each clinical setting in patients with HCC.

UR - http://www.scopus.com/inward/record.url?scp=84855336704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855336704&partnerID=8YFLogxK

U2 - 10.1159/000333275

DO - 10.1159/000333275

M3 - Review article

VL - 81

SP - 123

EP - 133

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - SUPPL. 1

ER -